Get the Stockscreener App
0.8604
5.14%
-0.0466
Tempest Therapeutics Inc stock is traded at $0.8604, with a volume of 737.08K.
It is down -5.14% in the last 24 hours and down -2.96% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$0.907
Open:
$0.9001
24h Volume:
737.08K
Relative Volume:
0.55
Market Cap:
$37.55M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-0.5624
EPS:
-1.53
Net Cash Flow:
$-28.18M
1W Performance:
-7.49%
1M Performance:
-2.96%
6M Performance:
-41.86%
1Y Performance:
-76.43%
1-Day Range:
$0.8601
$0.9148
1-Week Range:
$0.8601
$0.9514
52-Week Range:
$0.6986
$6.00
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.8604 | 37.55M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Decrease in Short Interest - Defense World
TPST stock rated a Sector outperform by Scotiabank - Knox Daily
Tempest gets fast track designation from FDA for amezalpat - MSN
A closer look at Tempest Therapeutics Inc (TPST)’s stock price trends - US Post News
Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Amezalpat (TPST-1120) - Marketscreener.com
Tempest Therapeutics Inc (TPST) Shares Rise Despite Market Challenges - The News Heater
Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer - Marketscreener.com
Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat - Marketscreener.com
Tempest Granted Fast Track Designation from the U.S. Food - GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Therapeutics Awards Strategic Compensation Package: Inside the 4-Year Vesting Deal - StockTitan
Analyzing Ratios: Tempest Therapeutics Inc (TPST)’s Financial Story Unveiled - The Dwinnex
A stock that deserves closer examination: Tempest Therapeutics Inc (TPST) - US Post News
Tempest Therapeutics Inc (NASDAQ: TPST) – An Analysis Is What You Need - Stocks Register
Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC - Defense World
Tempest Receives Orphan Drug Designation from the U.S. Food - GlobeNewswire
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewswire Inc.
Before You Sell Tempest Therapeutics Inc (NASDAQ: TPST) Shares, Here’sWhat You Need To Know. - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges - Investing.com Canada
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges By Investing.com - Investing.com South Africa
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Tempest Therapeutics amends rights agreement By Investing.com - Investing.com Australia
Tempest Therapeutics amends rights agreement - Investing.com India
Tempest Therapeutics Awards Key Employee Stock Options in Strategic Compensation Move | TPST Stock News - StockTitan
Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
William Blair Has Negative Estimate for TPST FY2024 Earnings - Defense World
Research Analysts Offer Predictions for TPST FY2024 Earnings - Defense World
500: Something went wrong - Investing.com Canada
TPST Stock Plummets to 52-Week Low at $0.85 Amid Market Struggles - Investing.com
HC Wainwright Reiterates “Buy” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler - TipRanks
TPSTTempest Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tempest Therapeutics advances liver cancer drug to Phase 3 trial By Investing.com - Investing.com Canada
Tempest Therapeutics reports Q3 EPS (41c), consensus (36c) - TipRanks
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Tempest Therapeutics advances liver cancer drug to Phase 3 trial - Investing.com India
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 - GlobeNewswire
Tempest Gets FDA Green Light for Pivotal Phase 3 Liver Cancer Drug Trial | TPST Stock | TPST Stock News - StockTitan
TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex
TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Tempest Therapeutics maintains stock target, sector outperform rating - Investing.com
Tempest Therapeutics maintains stock target, sector outperform rating By Investing.com - Investing.com South Africa
TPST stock touches 52-week low at $0.92 amid market challenges - Investing.com
Was Tempest Therapeutics Inc (TPST)’s session last reading good? - US Post News
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tempest Therapeutics Inc Stock (TPST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Aug 08 '24 |
Sale |
1.35 |
400,000 |
540,040 |
597,940 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 12 '24 |
Sale |
1.10 |
387,999 |
426,993 |
209,941 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):